Table 2.
Clinical pathological features of ccRCC patients (n = 311) from USA-ccRCC cohort
| Characteristic | Group | No. of cases | (%) |
|---|---|---|---|
| Age (year) | ≤ 60 | 133 | 42.77 |
| > 60 | 176 | 56.59 | |
| Gender | Male | 229 | 73.63 |
| Female | 82 | 26.37 | |
| Survival status | Alive | 80 | 25.72 |
| Dead | 231 | 74.28 | |
| Tumor type | Primary | 225 | 72.35 |
| Metastasis | 84 | 27.01 | |
| NA | 2 | 0.64 | |
| MSKCC (Memorial Sloan-Kettering Cancer Center) | Favorable risk | 100 | 32.15 |
| Intermediate risk | 135 | 43.41 | |
| Poor riak | 60 | 19.29 | |
| NA | 16 | 5.14 | |
| IMDC (International Metastatic Renal CellCarcinoma Database Consortium) | Favorable risk | 45 | 14.47 |
| Intermediate risk | 145 | 46.62 | |
| Poor riak | 56 | 18.01 | |
| NA | 65 | 20.90 | |
| Benefit | CB (Clinical benefit) | 89 | 28.62 |
| ICB (Intermediate clinical benefit) | 120 | 38.59 | |
| NCB (No clinical benefit) | 102 | 32.80 |